Asymmetric dimethylarginine as an independent risk marker for mortality in ambulatory patients with peripheral arterial disease.
Related Research units
Abstract
Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide (NO) synthesis causing endothelial dysfunction, an early sign of atherogenesis. Symmetric dimethylarginine (SDMA) does not inhibit NO synthases. Peripheral arterial disease (PAD) is a systemic indication of atherosclerosis.
Bibliographical data
| Original language | English |
|---|---|
| Article number | 3 |
| ISSN | 0954-6820 |
| Publication status | Published - 2011 |
| pubmed | 21175900 |
|---|
